The cosmetic surgery, facial aesthetics and medical lasers market is expected to double in size by 2017, exceeding $3 billion, according to a new report by iData Research, which specializes in medical device and pharmaceutical market research.
The report says the aesthetic laser and light therapy markets for skin resurfacing, hair removal, and laser lipolysis will be the fastest growing cosmetic procedure markets in the next seven years.
The market for botulinum toxin-A injectables—such as Botox—is estimated to grow to $543 million by 2017.
CEO of iData Dr. Kamran Zamanian had this to say about the “Botox wars”: ”Allergan has had a monopoly on botulinum toxin A drugs since 2002, but now faces competition from Dysport by Medicis as well as other new competitors expected to enter the market. Allergan and Medicis have been fierce rivals, as their Juvederm and Restylane facial dermal fillers compete in the lucrative dermal filler market.”
This competition will intensify further with the expected entry into the market of another botulinum toxin, PurTox by Mentor, according to the report. Mentor’s website says that PurTox is in Phase III clinical trials in the U.S.
Furthermore, the use of botulinum toxins is expected to increase given the growing number of therapeutic treatments it’s been approved for or may be approved for in the future; for example, the FDA is evaluating Botox as a treatment for severe migraines.
The U.S. market for injectables is currently valued at almost $860 million, according to the report, which is titled “Markets for Cosmetic Surgery, Facial Aesthetics and Medical Laser Devices 2011.” The report features data, analyses, and competitor profiles for botulinum toxins, dermal fillers, breast augmentation implants, liposuction aspirators, laser/light devices, and microdermabrasion.
